-
11.发明授权公开(公告)号：US10196451B2
公开(公告)日：2019-02-05
申请号：US15668305
申请日：2017-08-03
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US09765150B2
公开(公告)日：2017-09-19
申请号：US14950949
申请日：2015-11-24
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US08895010B2
公开(公告)日：2014-11-25
申请号：US13650493
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Abstract translation: 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
公开(公告)号：US11613585B2
公开(公告)日：2023-03-28
申请号：US17561529
申请日：2021-12-23
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Suzanne J. Suchard
IPC: C07K16/28 , A61K39/395
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US10919965B2
公开(公告)日：2021-02-16
申请号：US15870121
申请日：2018-01-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
Patent Agency Ranking
公开(公告)号：US20150299321A1
公开(公告)日：2015-10-22
申请号：US14740709
申请日：2015-06-16
Applicant: Bristol-Myers Squibb Company , Domantis Ltd.
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
Abstract translation: 公开了单价结合CD28的结构域抗体。 对CD28结合而言是单价的域抗体可抑制CD28活性。 在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。 另一方面，结构域抗体是人结构域抗体。 本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。
-
公开(公告)号：US08981072B2
公开(公告)日：2015-03-17
申请号：US14101441
申请日：2013-12-10
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
IPC: C12N15/13 , C12N15/12 , C12N5/10 , C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46 , A61K39/00 , A61K38/00
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Abstract translation: 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
公开(公告)号：US12012452B2
公开(公告)日：2024-06-18
申请号：US17086565
申请日：2020-11-02
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P37/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , C07K16/2896 , A61K2039/505 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
公开(公告)号：US11899017B2
公开(公告)日：2024-02-13
申请号：US16634833
申请日：2018-07-27
Applicant: Bristol-Myers Squibb Company
Inventor： Nataly Manjarrez Orduño , Suzanne J. Suchard
IPC: A61K39/395 , C07K16/28 , A61P35/00 , G01N33/574 , G01N33/569 , A61K45/06 , A61K39/00
CPC classification number: G01N33/57484 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/507 , G01N2800/52
Abstract: The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu (“hot tumor”) is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.
-
20.发明授权公开(公告)号：US11267888B2
公开(公告)日：2022-03-08
申请号：US16842885
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: A61K39/395 , C07K16/28 , A61K47/60 , A61K45/06 , A61K39/00
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.029 seconds)
